Revance falls after co withdraws annual forecast, extends deadline for tender offer

Revance Therapeutics

07/11/2024 23:29

** Shares of Anti-wrinkle injection maker Revance
Therapeutics  RVNC.O  fall 16.9% to $4.80 after the bell  
    ** Company says it will not be providing any forward-looking
guidance and is withdrawing any previously provided guidance in
light of its merger with Crown Labs 
    ** Adds, its deal has been delayed and has not yet commenced
    ** "Crown and Revance agreed to extend the deadline upon
which the tender offer must commence to November 12, 2024. The
tender offer has not yet commenced" - RVNC 
    ** Up to last close, stock down 32.24% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))